 |
| 18-Jan-13 | Reiterated |
MLV & Co |
Buy |
$40 → $21 |
|
| 24-Sep-12 | Reiterated |
Needham |
Buy |
$38 → $32 |
|
| 19-Jul-12 | Reiterated |
MLV & Co |
Buy |
$34 → $40 |
|
| 18-Jul-12 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$39 → $52 |
|
| 18-Jul-12 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 30-Apr-12 | Reiterated |
MLV & Co |
Buy |
$30 → $34 |
|
| 23-Feb-12 | Upgrade |
Rodman & Renshaw |
Mkt Perform → Mkt Outperform |
$39 |
|
| 23-Feb-12 | Upgrade |
Brean Murray |
Sell → Hold |
$2 |
|
| 23-Feb-12 | Reiterated |
MLV & Co |
Buy |
$22 → $30 |
|
| 23-Feb-12 | Reiterated |
JMP Securities |
Mkt Outperform |
$16 → $45 |
|
| 17-Jan-12 | Reiterated |
MLV & Co |
Buy |
$16 → $22 |
|
| 05-Jan-12 | Initiated |
Rodman & Renshaw |
Mkt Perform |
|
|
| 29-Oct-10 | Reiterated |
JMP Securities |
Mkt Outperform |
$12 → $16 |
|
| 03-Aug-10 | Downgrade |
Brean Murray |
Hold → Sell |
$2 |
|
| 16-Jul-10 | Reiterated |
Wedbush |
Outperform |
$20 → $10 |
|
| 16-Jul-10 | Reiterated |
JMP Securities |
Mkt Outperform |
$18 → $12 |
|
| 16-Jul-10 | Downgrade |
Jefferies |
Hold → Underperform |
$9 → $3 |
|
| 16-Jul-10 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 13-Jul-10 | Reiterated |
Brean Murray |
Buy |
$15 → $18 |
|
| 09-Jul-10 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
|
|
| 18-Jun-13 06:09PM | A.M.A. Recognizes Obesity as a Disease at New York Times |
| 17-Jun-13 01:42PM | Consumer Reports Says "Exercise" Rather Than Take This Drug at Motley Fool |
| 09:48AM | InPlay: Vivus: First Manhattan Co issues open letter to Vivus employees urging shareholders to vote for its nominees to the Board Briefing.com |
| 09:47AM | Open Letter to Vivus Employees Released by First Manhattan Co. Business Wire |
| 07:30AM | New Review Article Discusses Complications-Centric Approach to Obesity Medical Management With Qsymia GlobeNewswire |
| 07:01AM | InPlay: Vivus sends letter to shareholders; urges stockholders to support the Board and mgmt team by voting the gold proxy card Briefing.com |
| 07:00AM | VIVUS Urges Stockholders to Support the Board of Directors and Management Team at This Critical Time GlobeNewswire |
| 16-Jun-13 02:05PM | The Top 5 Diseases Caused by Obesity at Motley Fool |
| 15-Jun-13 02:00PM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 12-Jun-13 07:00AM | VIVUS to Present at Upcoming Investor Conference GlobeNewswire |
| 11-Jun-13 08:08PM | The Obesity-Drug Wars Officially Begin at Motley Fool |
| 02:31PM | An Obesity Drug Stock to Fatten your Portfolio? at Motley Fool |
| 09-Jun-13 02:05PM | The 3 Biggest Risk Factors for a Stroke at Motley Fool |
| 07-Jun-13 06:32PM | New Obesity Drug Hits the Market at Motley Fool |
| 02:52PM | 5 stocks insiders are buying at MarketWatch |
| 01:26PM | Arena Launches Belviq - Buying Opportunity at Seeking Alpha |
| 11:40AM | Weight loss drug Belviq gets overdue US launch AP |
| 11:12AM | Weight loss drug Belviq gets overdue US launch AP |
| 07:01AM | InPlay: Vivus: New article discusses treatment options for weight management in people with type 2 diabetes; Qsymia cited as treatment option Briefing.com |
| 07:00AM | New Article Discusses Treatment Options for Weight Management in People With Type 2 Diabetes GlobeNewswire |
| 06-Jun-13 06:54PM | Sarissa's Stake in VIVUS Points to Renewed Interest in the Company at Motley Fool |
| 12:18PM | Pfizer's Big Chance at Motley Fool |
| 12:20AM | Vivus Fighting 3 Front War at Seeking Alpha |
| 05-Jun-13 07:16PM | 4 Healthcare Stock Stories For Midweek Investment Wellness at Wall St. Cheat Sheet |
| 01:48PM | InPlay: Vivus files definitive proxy materials with SEC; urges stockholders to vote 'for' the Board's nominees on gold proxy card Briefing.com |
| 01:45PM | VIVUS Files Definitive Proxy Materials With SEC GlobeNewswire |
| 09:18AM | What Must Be In The Ideal Biopharmaceutical Portfolio? at Seeking Alpha |
| 03:23AM | Arena's Belviq Set To Launch at Seeking Alpha |
| 04-Jun-13 02:51PM | Hedge Fund ETF Celebrates First Birthday in Style ETF Trends |
| 01:02PM | First Manhattan seeks to replace Vivus directors AP |
| 11:56AM | Arena And Vivus Investors: Do Not Fear A Market Correction at Seeking Alpha |
| 11:18AM | InPlay: Vivus: First Manhattan mails definitive proxy statement and sends letter to Vivus stockholders; urges Vivus stockholders to vote the white proxy card Briefing.com |
| 11:15AM | First Manhattan Mails Definitive Proxy Statement and Sends Letter to Vivus Stockholders Business Wire |
| 03-Jun-13 04:05PM | Recent Insider Buying Just One More Reason To Consider Vivus at Seeking Alpha |
| 07:00AM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 31-May-13 01:46PM | Stocks to Buy: Biotechs With Growth Potential at Motley Fool |
| 10:22AM | Opko Health CEO Buys 54K Shares and 4 Insider Trades to Note at Wall St. Cheat Sheet |
| 09:47AM | VIVUS INC Files SEC form 8-K, Other Events EDGAR Online |
| 01:31AM | The Arena Pipeline Potential at Seeking Alpha |
| 30-May-13 09:30PM | VIVUS' Management Presents at Deutsche Bank dbAccess Health Care Conference (Transcript) at Seeking Alpha |
| 08:18AM | Is Novo A Threat To Arena, Vivus, And Orexigen? at Seeking Alpha |
| 29-May-13 07:11PM | Arena: Marketing An Anti-Obesity Drug at Seeking Alpha |
| 02:50PM | This Obesity Drugmaker Is Badly In Need of a Marketing Partner at Motley Fool |
| 02:23PM | Commit To Buy Vivus At $8, Earn 16.9% at Forbes |
| 01:45PM | 3 Big Reasons to Own Johnson & Johnson Stock at Motley Fool |
| 09:39AM | The Newest Obesity Drug Player at Motley Fool |
| 09:27AM | Sales Estimates For Arena's Belviq Are Too Low And Shares Are Undervalued at Seeking Alpha |
| 27-May-13 08:00AM | 2 Biotech Stocks in Activist Investors' Crosshairs at Motley Fool |
| 26-May-13 02:15PM | The 7 Most Obese U.S. States at Motley Fool |
| 25-May-13 03:10PM | The 7 Least Obese U.S. States at Motley Fool |
| 02:15PM | The Top 3 Causes of Diabetes at Motley Fool |
| 24-May-13 04:18PM | 3 Humongous Health Care Stocks This Week at Motley Fool |
| 11:02AM | What's behind put trading in Vivus optionMONSTER |
| 11:02AM | What's behind put action in Vivus optionMONSTER |
| 10:27AM | Why This Obesity Drug Is the Sector's Best Bet at Motley Fool |
| 06:20AM | Novo obesity drug could launch in U.S. end 2014 at Reuters |
| 05:41AM | Vivus Heats Up, Shorts Discouraged On Possible Bidding War at Seeking Alpha |
| 02:53AM | Arena - Good Sales, Bad Sales, Long And Short at Seeking Alpha |
| 12:06AM | First Manhattan Still Playing Hardball With Vivus at Seeking Alpha |
| 23-May-13 04:51PM | Denner added as nominee to Vivus board by activist investor at Reuters +7.25% |
| 04:21PM | Bullish Two Hundred Day Moving Average Cross - VVUS at TheStreet |
| 03:26PM | [video] Options Activity Ahead of Pandora Earnings at CNBC |
| 01:55PM | Why This Obesity Drug Is the Sector's Best Bet at Motley Fool |
| 01:02PM | [video] Nasdaq Check: Tech Stocks Recover at CNBC |
| 09:35AM | Alex Denner Joins Vivus Activist Slate in Post-Icahn Move at Bloomberg |
| 06:31AM | InPlay: Vivus: First Manhattan adds Alex Denner to Vivus Board slate; Denner's Sarissa Capital Management owns 2 mln Vivus shares Briefing.com |
| 06:30AM | First Manhattan Adds Alex Denner to Vivus Board Slate Business Wire |
| 22-May-13 08:56PM | 3 Pipeline Obesity Treatments You Should Watch at Motley Fool |
| 07:00AM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 03:19AM | Arena Pharmaceuticals - Out To Launch Or Out To Lunch? at Seeking Alpha |
| 21-May-13 09:06AM | VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o EDGAR Online |
| 06:56AM | The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does at Seeking Alpha |
| 20-May-13 02:06PM | The 9 Most Obese Countries in the World at Motley Fool +5.53% |
| 19-May-13 09:41AM | Vivus Taps Into More Cash at Seeking Alpha |
| 18-May-13 08:01AM | 25 Belt-Busting Obesity Facts at Motley Fool |
| 16-May-13 10:22AM | VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme EDGAR Online |
| 07:02AM | InPlay: Vivus prices offering of $220 mln aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 Briefing.com |
| 07:00AM | VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes GlobeNewswire |
| 15-May-13 07:04PM | Weight Loss Isn't Just for Looking Good Anymore at Motley Fool -5.00% |
| 01:28PM | Is Vivus a Buy at These Prices? at Wall St. Cheat Sheet |
| 01:04PM | VIVUS INC Financials EDGAR Online Financials |
| 11:38AM | Vivus to sell $200 million in convertible debt AP |
| 10:18AM | Vivus - Mild Drama Continues at Seeking Alpha |
| 08:42AM | Will Obesity Drugs Gain Soon? at Motley Fool |
| 07:02AM | InPlay: Vivus announces offering of $200 mln aggregate principal amount of convertible senior unsecured notes due May 1, 2020 Briefing.com |
| 07:00AM | VIVUS Announces Proposed Offering of Convertible Senior Notes GlobeNewswire |
| 12:06AM | VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 14-May-13 02:19PM | Analysts: Market Is Beginning to Recognize Tesla and 3 Other Research Notes to Check Out at Wall St. Cheat Sheet |
| 07:00AM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 05:49AM | Looking at Arena Following Sell-Off at Motley Fool |
| 05:42AM | Vivus Starting To Gain The Advantage Over Arena at Seeking Alpha |
| 01:16AM | Shorting Arena Is Not a Good Idea Now at Motley Fool |
| 01:08AM | Arena, Vivus, And Off-Label Prescriptions at Seeking Alpha |
| 13-May-13 04:18PM | Vivus Adds Two New Directors to Board Amid Pressure at Bloomberg |
| 01:24PM | Vivus Increases Board to 9 Members at Motley Fool |
| 11:28AM | Starbucks Looks to Myanmar, Delta and United Grapple With New Flu, and 2 Other Hot Stocks at Wall St. Cheat Sheet |
| 11:17AM | Vivus names 2 new directors to its board AP |
| 09:33AM | Vivus Adds Two New Directors to Board Amid Pressure at Bloomberg |
| 07:05AM | VIVUS Mails Letter to Stockholders Providing Business Update GlobeNewswire |
| 07:00AM | VIVUS Appoints J. Martin Carroll and Jorge Plutzky, M.D. to Board of Directors GlobeNewswire |
|
|
| VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MARIO ERNEST | Director | May 29 | Buy | 14.68 | 15,000 | 220,206 | 81,125 | May 30 01:54 PM | | CASAMENTO CHARLES J | Director | Aug 20 | Option Exercise | 5.69 | 8,000 | 45,520 | 74,000 | Aug 21 07:00 PM | | MARIO ERNEST | Director | Aug 20 | Buy | 20.75 | 5,000 | 103,750 | 45,000 | Aug 21 07:03 PM | | CASAMENTO CHARLES J | Director | Aug 20 | Sale | 20.63 | 8,000 | 165,060 | 66,000 | Aug 21 07:00 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 14 | Option Exercise | 4.60 | 18,000 | 82,820 | 15,000 | Aug 15 07:53 PM | | LOGAN MARK B | Director | Aug 14 | Option Exercise | 5.64 | 49,816 | 280,838 | 75,000 | Aug 15 07:54 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 14 | Sale | 22.72 | 18,000 | 409,000 | 5,000 | Aug 15 07:53 PM | | LOGAN MARK B | Director | Aug 14 | Sale | 23.13 | 49,816 | 1,152,169 | 53,000 | Aug 15 07:54 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 13 | Option Exercise | 4.25 | 20,000 | 85,000 | 25,000 | Aug 14 06:47 PM | | LOGAN MARK B | Director | Aug 13 | Option Exercise | 4.25 | 18,184 | 77,282 | 71,184 | Aug 14 06:52 PM | | LOGAN MARK B | Director | Aug 13 | Sale | 21.81 | 18,184 | 396,580 | 53,000 | Aug 14 06:52 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 13 | Sale | 22.00 | 20,000 | 440,000 | 5,000 | Aug 14 06:47 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 10 | Option Exercise | 4.23 | 25,000 | 105,750 | 30,000 | Aug 14 06:47 PM | | MARIO ERNEST | Director | Aug 10 | Buy | 21.50 | 5,000 | 107,500 | 40,000 | Aug 13 06:00 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 10 | Sale | 21.50 | 25,000 | 537,500 | 5,000 | Aug 14 06:47 PM | | MARIO ERNEST | Director | Aug 09 | Buy | 21.83 | 15,000 | 327,399 | 35,000 | Aug 13 06:00 PM | | Slebir John L | VP, General Counsel | Jul 18 | Option Exercise | 7.27 | 10,000 | 72,713 | 10,376 | Jul 20 07:21 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jul 18 | Option Exercise | 10.19 | 25,000 | 254,750 | 32,943 | Jul 20 07:07 PM | | MARSH GUY P | VP, Operations and General Mgr | Jul 18 | Option Exercise | 4.69 | 36,191 | 169,664 | 25,713 | Jul 20 07:10 PM | | WILSON LELAND F | CEO | Jul 18 | Option Exercise | 3.34 | 100,000 | 333,754 | 169,427 | Jul 20 07:12 PM | | MORRIS TIMOTHY E | VP, Finance and CFO | Jul 18 | Option Exercise | 4.23 | 25,000 | 105,750 | 25,000 | Jul 20 07:14 PM | | TAM PETER Y | President | Jul 18 | Option Exercise | 4.25 | 25,000 | 106,250 | 62,629 | Jul 20 07:17 PM | | TAM PETER Y | President | Jul 18 | Sale | 30.95 | 25,000 | 773,750 | 37,629 | Jul 20 07:17 PM | | MORRIS TIMOTHY E | VP, Finance and CFO | Jul 18 | Sale | 30.36 | 25,000 | 759,000 | 0 | Jul 20 07:14 PM | | WILSON LELAND F | CEO | Jul 18 | Sale | 30.36 | 100,000 | 3,036,000 | 119,112 | Jul 20 07:12 PM | | MARSH GUY P | VP, Operations and General Mgr | Jul 18 | Sale | 30.36 | 36,191 | 1,098,759 | 2,074 | Jul 20 07:10 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jul 18 | Sale | 30.36 | 25,000 | 759,000 | 7,943 | Jul 20 07:07 PM | | Slebir John L | VP, General Counsel | Jul 18 | Sale | 30.36 | 10,000 | 303,600 | 4,126 | Jul 20 07:21 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 27 | Option Exercise | 10.19 | 25,000 | 254,750 | 32,943 | Jun 29 05:01 PM | | WILSON LELAND F | CEO | Jun 27 | Option Exercise | 4.15 | 50,000 | 207,500 | 169,112 | Jul 02 09:49 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 27 | Sale | 28.08 | 25,000 | 701,900 | 7,943 | Jun 29 05:01 PM | | WILSON LELAND F | CEO | Jun 27 | Sale | 28.00 | 50,000 | 1,400,000 | 119,112 | Jul 02 09:49 PM | | TAM PETER Y | President | Jun 19 | Option Exercise | 3.73 | 20,000 | 74,600 | 57,629 | Jun 20 07:29 PM | | TAM PETER Y | President | Jun 19 | Sale | 27.25 | 20,000 | 545,000 | 37,629 | Jun 20 07:29 PM |
|
|
|
|
|
|
